Which medication is described as a once-weekly GLP-1 receptor agonist?

The medication described as a once-weekly GLP-1 receptor agonist is Trulicity.

Trulicity, also known as dulaglutide, is an injectable medication that is administered once a week to help manage blood sugar levels in individuals with type 2 diabetes. It mimics the action of the GLP-1 hormone by stimulating insulin release in response to high blood sugar levels, decreasing glucagon secretion, and slowing gastric emptying, which helps to reduce appetite and promote weight loss.

Understanding the other medications provides context. Mounjaro, which is not the correct choice, is a newer GLP-1 receptor agonist but is typically administered differently, with its dosing schedule still needing clarification among users. Rybelsus is a daily oral GLP-1 receptor agonist, which further distinguishes it from Trulicity, emphasizing that while it also works on similar pathways, it is dosed every day rather than weekly. Therefore, Trulicity stands out as the clear choice for a once-weekly GLP-1 receptor agonist, highlighting its convenience for patients in terms of compliance and management of diabetes.